{"filings":[{"id":99934,"accession_number":"0001193125-26-197282","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ResMed CFO Brett Sandercock retires; Aaron Bloomer appointed successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brett Sandercock retires as CFO effective May 4, 2026; remains special advisor to CEO through Dec 2027.","Aaron Bloomer appointed CFO effective May 4; previously CFO of Exact Sciences (recently acquired by Abbott).","Bloomer compensation: $725k salary, $150k sign-on bonus, $3.3M equity grant (RSUs/PSUs with TSR metrics).","Resmed reiterates FY2026 guidance: gross margin 62-63%, SG&A 19-20%, R&D 6-7%, tax rate 21-23%.","Sandercock's retirement not due to any disagreement; retains salary, benefits and equity vesting through 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99933,"accession_number":"0001193125-26-197192","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed Q3 revenue $1.43B (+11%); GAAP EPS $2.74, dividend $0.60","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1,431.4M (+11% reported, +8% constant currency).","GAAP diluted EPS $2.74 (+10% YoY); non-GAAP diluted EPS $2.86 (+21% YoY).","GAAP gross margin 62.2% (+290 bps); non-GAAP gross margin 62.8% (+290 bps).","Quarterly dividend $0.60/share declared; record 5/14/2026, payable 6/18/2026.","Operating cash flow $554M; $262M returned via buybacks and dividends in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":7.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":4189796000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116233,"accession_number":"0001193125-26-029326","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed Q2 FY2026: Revenue $1.42B (+11% YoY), non-GAAP EPS $2.81, dividend $0.60","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1,422.8M, up 11% YoY (9% constant currency); gross margin expanded 320 bps to 61.8%.","GAAP diluted EPS $2.68; non-GAAP diluted EPS $2.81, up 16% YoY.","Operating cash flow $340M; income from operations rose 18% YoY.","Board declared quarterly cash dividend of $0.60/share, record Feb 12, payable Mar 19."],"consensus_eps_estimate":null,"consensus_eps_actual":5.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":2758390000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132694,"accession_number":"0001193125-25-289878","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Director Sulpizio not re-elected; board shrinks to 11; stockholders approve equity plan amendments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Richard Sulpizio did not seek re-election at Nov 19 annual meeting; board reduced from 12 to 11 directors.","Stockholders approved 2009 Incentive Award Plan amendment, adding 2.4M shares and eliminating fixed term.","Stockholders approved ESPP amendment, adding 3.0M shares and eliminating fixed term.","All 11 director nominees elected; KPMG ratified as auditor; say-on-pay approved (98.4M for, 11.0M against).","Plan amendments effective upon stockholder approval; detailed terms incorporated by reference to proxy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132693,"accession_number":"0001193125-25-258519","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed Q1 FY2026 revenue +9% to $1.34B; non-GAAP EPS $2.55 (+16%); dividend $0.60","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1,335.6M (+9% YoY, +8% constant currency); diluted EPS $2.37, non-GAAP EPS $2.55 (+16%).","Gross margin up 290 bps to 61.5%; non-GAAP gross margin 62.0% (up 280 bps).","Operating cash flow $457M; income from operations +15% (+19% non-GAAP).","Board declared quarterly dividend of $0.60 per share, payable Dec 18 to holders of record Nov 13."],"consensus_eps_estimate":null,"consensus_eps_actual":2.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":1335582000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149213,"accession_number":"0001193125-25-182695","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ResMed elects AbbVie's Nicole Mowad-Nassar to board; director Sulpizio to retire in Nov 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nicole Mowad-Nassar elected to ResMed board effective Aug 15, 2025; she is SVP at AbbVie and President of Specialty & U.S. Therapeutics Operations.","She will serve on the Compensation and Leadership Development Committee; term expires at 2025 annual meeting on Nov 19, 2025.","Director Richard Sulpizio to retire after 20 years, not standing for reelection at Nov 19 meeting; no disagreement with company.","Sulpizio previously chaired Compensation, Audit, and Nominating & Governance committees during his tenure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149212,"accession_number":"0001193125-25-170718","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ResMed CCO of residential care software business resigns effective Aug 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bobby Ghoshal, chief commercial officer of ResMed's RCS business, resigns effective August 1, 2025.","He is departing to become COO of a software company in a non-competitive industry.","No replacement has been announced; resignation is voluntary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149211,"accession_number":"0001193125-25-170512","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed Q4 revenue up 10% to $1.35B, EPS $2.58; dividend raised 13% to $0.60","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $1.35B (+10% YoY, +9% CC); GAAP EPS $2.58 (+30%), non-GAAP EPS $2.55 (+23%).","Gross margin up 230bps to 60.8% GAAP; operating income $454.5M (+19%).","FY2025 revenue $5.15B (+10%); GAAP EPS $9.51 (+37%).","Dividend raised 13% to $0.60/share; payable Sept 18, record Aug 14; ex-div Aug 13."],"consensus_eps_estimate":null,"consensus_eps_actual":9.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":5146327000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168231,"accession_number":"0001193125-25-091357","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed Q3 FY2025: revenue $1.29B (+8%), GAAP EPS $2.48 (+22%), non-GAAP EPS $2.37 (+11%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $1.29B (+8% YoY; +9% constant currency); GAAP diluted EPS $2.48 vs $2.04 (+22%).","Gross margin improved 140 bps to 59.3%; non-GAAP gross margin 59.9%.","Operating income up 14% to $426.3M; non-GAAP operating income up 13% to $444.6M.","Operating cash flow of $579M in the quarter.","Quarterly dividend of $0.53/share declared; payable June 12, 2025 to holders of record May 8, 2025."],"consensus_eps_estimate":2.5799,"consensus_eps_actual":6.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":3798334000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185422,"accession_number":"0001193125-25-017218","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed reports Q2 FY2025 revenue up 10% to $1.28B; non-GAAP EPS $2.43, up 29%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.28B (+10% YoY); gross margin 58.6% (+300 bps) on manufacturing efficiencies.","Non-GAAP diluted EPS $2.43 (+29%); operating income $417M (+52% vs $275M, prior year had $64M restructuring).","Operating cash flow $309M; paid $78M dividends and repurchased $75M shares during quarter.","Board declared $0.53 quarterly dividend; record Feb 13, 2025, payable Mar 20, 2025.","Residential Care Software revenue up 8% constant currency; U.S./Canada/Latin America revenue up 12%."],"consensus_eps_estimate":null,"consensus_eps_actual":4.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":2506598000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202007,"accession_number":"0001193125-24-263501","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ResMed stockholders elect all 11 director nominees, ratify KPMG, approve say-on-pay at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 11 director nominees elected with strong support; vote tallies ranged from ~88M to ~109M in favor.","KPMG LLP ratified as independent auditor for fiscal 2025 with 105,082,628 for, 10,096,722 against.","Advisory say-on-pay resolution approved with 92,885,004 for, 17,284,647 against.","No material changes to board composition or executive compensation structure disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202006,"accession_number":"0001193125-24-242806","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed Q1 FY2025 revenue $1.22B (+11% YoY); EPS $2.11; non-GAAP EPS $2.20; dividend $0.53","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1,224.5M, up 11% YoY (11% constant currency), driven by sleep device and mask demand.","GAAP diluted EPS $2.11; non-GAAP diluted EPS $2.20, up 34% YoY; operating profit up 34%.","Gross margin improved to 58.6% (non-GAAP 59.2%), up 420 bps YoY on manufacturing efficiencies.","Operating cash flow $326M; paid $78M dividends and repurchased $50M shares.","Board declared quarterly dividend of $0.53 per share, record date Nov 7, payable Dec 12."],"consensus_eps_estimate":null,"consensus_eps_actual":2.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":1224509000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218049,"accession_number":"0001193125-24-202204","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ResMed appoints Christopher DelOrefice to board of directors, effective August 15, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["DelOrefice is EVP and CFO of Becton Dickinson, brings 30+ years of audit, finance and strategic expertise.","Board expanded to 11 members; DelOrefice will serve on audit committee.","Appointment effective immediately; will stand for re-election at Nov 21, 2024 annual meeting.","DelOrefice previously served as VP Investor Relations at Johnson & Johnson and CFO of North America Hospital Medical Devices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218048,"accession_number":"0001193125-24-191487","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed Q4 revenue $1.22B (+9% YoY); EPS $1.98; dividend up 10% to $0.53","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 FY2024 revenue $1,223.2M (+9% YoY, +10% constant currency); gross margin 58.5% (+350 bps).","GAAP diluted EPS $1.98 (+27% YoY); non-GAAP diluted EPS $2.08 (+30% YoY).","Operating cash flow $440M; debt repayments of $300M in Q4; FY2024 operating cash flow $1.4B.","Quarterly dividend increased 10% to $0.53 per share (payable Sept 19, record Aug 15).","Investor Day announced for September 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":6.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":4685297000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237998,"accession_number":"0001193125-24-113883","cik":943819,"company_name":"RESMED INC","ticker":"RMD","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ResMed Q3 FY2024 revenue $1.20B, +7% YoY; GAAP EPS $2.04, non-GAAP $2.13","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.197B up 7% YoY (7% constant currency); mask/accessories double-digit growth.","Gross margin expanded 260 bps to 57.9%; non-GAAP 58.5%.","Operating profit $374.6M (+25%); non-GAAP operating profit $393.6M (+23%).","Diluted GAAP EPS $2.04 (+29%); non-GAAP EPS $2.13 (+27%).","Quarterly dividend $0.48, record May 9, payable June 13."],"consensus_eps_estimate":null,"consensus_eps_actual":4.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":3462102000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29896122701.21214,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}